FLT3 is a kinase mutated in about a third of acute myeloid leukaemias, where adding an inhibitor to chemotherapy improves survival. This dossier gathers the 5 products (5 approved), 3 trials, 1 pathway and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Class III receptor tyrosine kinase; ITD confers poor prognosis.
- Acute myeloid leukaemia
Elsewhere: identifiers and databases
Built from HGNC, Ensembl, UniProt and ChEMBL idsHow common it is, by cancer
Full matrix →| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Acute myeloid leukaemia | 25-30% | FLT3-ITD or TKD | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Mutation hotspots and which drugs address them
| Residue | Kind | How common | What it does | Addressed by | Defeats | Source |
|---|---|---|---|---|---|---|
| Internal tandem duplication (ITD) 572 to 603 | Activating | About 25% of AML | In-frame duplications in the juxtamembrane domain; high allelic ratio and long insertions carry worse prognosis. Every approved FLT3 inhibitor covers ITD. | — | Daver et al., Leukemia 2019 | |
| D835Y/V/H (TKD) 835 | Activating | About 7% of AML | Activation-loop mutation. Type I inhibitors (midostaurin, gilteritinib) cover it; type II quizartinib does not, and D835 emerges as resistance to quizartinib. | Daver et al., Leukemia 2019 | ||
| F691L (gatekeeper) 691 | Resistance | not sourced | Acquired after gilteritinib or quizartinib; reduces sensitivity to both classes. | none in corpus | Daver et al., Leukemia 2019 |
Frequencies are quoted from the source on each row; a blank means no figure was sourced, not that it is rare. Domain boundaries are approximate. Sources for the map: COSMIC: FLT3.
Products by modality and phase
Browse products →| Modality | Approved |
|---|---|
| Small molecule 5 |
Trials
Evidence ranking →| Trial | Phase | Status | Setting | Result | Products |
|---|---|---|---|---|---|
| QuANTUM-First NCT02668653 | 3 | Positive | Newly diagnosed FLT3-ITD AML, age 18-75: quizartinib vs placebo with 7+3, consolidation, and up to 3 years of maintenance | OS 31.9 vs 15.1 months; HR 0.776. | |
| ADMIRAL NCT02421939 | 3 | Positive | Relapsed or refractory FLT3-mutated AML: gilteritinib monotherapy vs salvage chemotherapy | OS 9.3 vs 5.6 months; HR 0.64. | |
| RATIFY (CALGB 10603) NCT00651261 | 3 | Positive | Newly diagnosed FLT3-mutated AML, age 18-59: midostaurin vs placebo added to 7+3, consolidation, and one year of maintenance | Median OS 74.7 vs 25.6 months; HR 0.78. |
Resistance routes that involve this target
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways where it is a node
Pathway-to-drug matrix →- Menin / KMT2A (HOXA9-MEIS1 axis)Node: FLT3 (co-mutated; co-target) · 2 druggable nodes
In some leukaemias a broken chromatin protein (KMT2A, once called MLL) or a mutant NPM1 keeps embryonic growth genes (HOXA9, MEIS1) switched on, so blood cells never mature. Both need a partner called menin to stay on the DNA. Menin inhibitors pull the plug and the cells mature; the first was approved in 2024.
Which nodes have drugs →
Companion diagnostics and assays
Assay registry →| Assay | Platform | Cut-off | Gates |
|---|---|---|---|
| LeukoStrat CDx FLT3 Mutation Assay Invivoscribe · FDA CDx 2017 | PCR | ITD signal ratio at least 0.05 or TKD mutation detected (midostaurin, gilteritinib); ITD only for quizartinib |
Preclinical models
All models →| Cell line | Identifiers | Why it is used |
|---|---|---|
| MOLM-13 | CVCL_2119 · ACH-000362 | ITD heterozygous. |
| MV4-11 | CVCL_0064 · ACH-000045 | ITD homozygous. |
| MOLM-14 | CVCL_7916 · ACH-001574 | ITD; sister line of MOLM-13. |
| Ba/F3 FLT3-ITD and D835Y | not resolved | Engineered alleles including F691L gatekeeper. |
- Flt3-ITD knock-in (Endogenous ITD) Lee et al., Cancer Cell 2007
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Ideas and companies
Key papers and the live literature
Preprints →- QuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML · The Lancet 2023
- ADMIRAL: gilteritinib pills versus chemotherapy for relapsed FLT3-mutated acute myeloid leukaemia · New England Journal of Medicine 2019
Query for this target: (TITLE:"FLT3" OR ABSTRACT:"FLT3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FLT3, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/flt3.json. Licence CC BY 4.0.